Kuhnt M, Bitsch F, France J, Hofmann H, Sanglier J J, Traber R
Preclinical Research, Sandoz Pharma Ltd, Basle, Switzerland.
J Antibiot (Tokyo). 1996 Aug;49(8):781-7. doi: 10.7164/antibiotics.49.781.
In order to mimic the human metabolic pathway of cyclosporin A (CyA) a total of 28 bacterial and 72 fungal strains was screened for their ability to transform CyA. Among 3 bacteria and 11 fungi, which produced the main human metabolite OL-17 [eta HyMeBmt1]CyA, Actinoplanes sp. (ATCC 53771) achieved the best transformation rate (5.4%). Furthermore, the two N-demethylated minor products [Leu4]CyA (3.2%) and [Leu9]CyA (4.7%) were isolated, both known as minor natural metabolites and the first one also as a human biotransformation product. Microbial conversion of CyA using the actinomycete Sebekia benihana (NRRL 11111) yielded [gamma HyMeLeu4]CyA (35%), [gamma HyLeu4]CyA (4.5%) and [gamma HyMeLeu4, gamma HyMeLeu6]CyA (8.6%). The structures of these derivatives correspond with those of the human metabolic pathway. The related compounds [Nva2]CyA (CyG) and [D-MeSer3]CyA were similarly converted to the corresponding 4-gamma-hydroxylated analogues. None of the biotransformation products showed a better immunosuppressive effect than CyA, although in various cases the cyclophilin binding affinity was comparable to that of CyA.
为了模拟环孢素A(CyA)的人体代谢途径,共筛选了28株细菌菌株和72株真菌菌株转化CyA的能力。在3株细菌和11株真菌中,它们产生了主要的人体代谢产物OL-17 [eta HyMeBmt1]CyA,其中游动放线菌(ATCC 53771)的转化率最高(5.4%)。此外,还分离出了两种N-去甲基化的次要产物[Leu4]CyA(3.2%)和[Leu9]CyA(4.7%),这两种产物均为已知的次要天然代谢产物,第一种还作为人体生物转化产物。使用贝内哈纳链霉菌(NRRL 11111)对CyA进行微生物转化,得到了[gamma HyMeLeu4]CyA(35%)、[gamma HyLeu4]CyA(4.5%)和[gamma HyMeLeu4, gamma HyMeLeu6]CyA(8.6%)。这些衍生物的结构与人体代谢途径中的结构相对应。相关化合物[Nva2]CyA(CyG)和[D-MeSer3]CyA也同样被转化为相应的4-γ-羟基化类似物。尽管在各种情况下亲环蛋白结合亲和力与CyA相当,但没有一种生物转化产物的免疫抑制作用比CyA更好。